milliporesigma videos

31. Explore The M Lab Collaboration Center In Burlington MA 9/19/2022

    Our global network of scientific experts, innovative technologies, and non-GMP facilities, empower drug developers of all sizes to achieve manufacturing excellence and innovation through collaborative exploration and learning. Explore 1 of our 8 global facilities today.

32. SF-RVN® Platform For Improving The Safety Profile Of Your Therapies 7/19/2022

    Discover how our Insect Cell Line provides a high performance platform optimal to produce recombinant proteins, viral vaccines, and adeno-associated vectors (AAV) for gene therapy applications.

33. Combining Expertise With Best-In-Class Technology 10/20/2021

    Members of the MilliporeSigma leadership team reflect on the longstanding experience of our BioReliance® viral vector manufacturing facilities. Our legacy experience, alongside our brand new facility and latest industry innovations, ensure we are a preferred partner to pioneer the path to cures.

34. How MilliporeSigma Promotes Quality And Risk Reduction 10/20/2021

    Learn how MilliporeSigma’s new facility was built with quality and risk reduction at the top of mind and its experts have the experience to support large-scale programs through commercialization.

35. MilliporeSigma Large Scale Capabilities Tour 10/20/2021

    A detailed look at MilliporeSigma’s new BioReliance® viral vector manufacturing facility and how we have employed the latest innovations and quality systems to deliver best-in-class gene therapy services.

36. Release Your Gene Therapy With Confidence 7/20/2021

    You are developing a cell or gene therapy and now you need to deliver it quickly to patients. But first you must make sure it's safe and effective. That's where we come in. Our experts can draw a testing strategy for your specific product, process, and goals.

37. Increasing The Reach Of Cell And Gene Therapies 4/29/2021

    The cell and gene therapy industry is rapidly evolving from the perspective of “can we commercialize this class of therapeutics?” to “how do we reach patients who need these therapies?”. However, the promise of these biologics can only be realized if the industry approaches manufacturing parity with monoclonal antibodies. A mixture of innovation and brute-force streamlining is needed to create viable cell and gene therapy templates. In this video, we discuss how upstream process optimization is ripe for innovative approaches.

38. NovaSeptum® GO Sterile Sampling: Total Cost Of Ownership 8/24/2020

    Risk of contamination associated with traditional sampling methods using SIP valve/welding can have a financial impact on your process sampling plan. Find out how much NovaSeptum® GO sterile sampling system can save you by reducing operator related costs while drastically reducing sample contamination risk and sample loss.

39. NovaSeptum® GO Sterile Sampling: Benefits Of A Fully Harmonized Solution 8/24/2020

    Harmonization of sampling processes across your entire biomanufacturing production is possible using sterile sampling methods. Learn how to implement sterile sampling solutions that meets and exceeds sampling and sample storage/retainment guidelines and to reduce contamination risk during process sampling.

40. Avoid Costly Process Development Mistakes 6/22/2020

    Costly mistakes can happen when rushing through process development to produce curative therapies for genetic diseases.  Learn about 3 key strategies that can be leveraged to improve product yield, quality, and patient safety.